Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants,
young children, and older or immunocompromised adults. Although aerosolized ribavirin …

Respiratory Syncytial Virus (RSV) is a common virus that infects children and adults;
however, children younger than two years of age tend to develop more serious respiratory …

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract
infections in infants and young children, accounting for more than 100,000 hospitalizations …

Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Respiratory syncytial virus (RSV) is an important respiratory pathogen in infants and children
worldwide. Although RSV typically causes mild upper respiratory infections, it frequently …

Abstract Introduction The REGAL (RSV Evidence–A Geographical Archive of the Literature)
series has provided a comprehensive review of the published evidence in the field of …

Palivizumab was licensed in June 1998 by the US Food and Drug Administration for
prevention of serious lower respiratory tract disease caused by respiratory syncytial virus …

The Food and Drug Administration recently approved the use of palivizumab (palē-vizhū-
mäb), an intramuscularly administered monoclonal antibody preparation …

Abstract The Food and Drug Administration recently approved the use of palivizumab (pale-
vizhumab), an intramuscularly administered monoclonal antibody preparation …

Introduction: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract
infections (LRTI) in infants, the elderly, and the immunocompromised. Although the …